As an initial study exploring pharmaceutical strategy for AD at such an old age, we have demonstrated that SCF+G-CSF treatment reduces Aβ deposits, ameliorates neuroinflammation, and increases the densities of dendrites and synapses in the brains of the very old APP/PS1 mice. Here, KITLG is linked to Alzheimer disease.